Sanofi May Get EU Double Whammy After French Fine For Hindering Entry Of Plavix Generics
Echoing the European Commission’s probe into whether drug companies blocked regional entry of cheaper generics, France’s Competition Authority has fined Sanofi €40.6 million for hindering domestic access to generic equivalents of its blockbuster clot-buster Plavix.
You may also be interested in...
VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.